GlassScriptPhysician profile
Ivan Soosaipillai
NPI 1649289059
$12,192.07
in general payments reported to CMS, 2019-2025
27 companies · $2,068 in 2025
The $2,068 reported for 2025 was more than what 86% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,455 · 2020: $1,453 · 2021: $1,604 · 2022: $1,086 · 2023: $1,179 · 2024: $1,347 · 2025: $2,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,495 · Education: $99.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,494.77 |
| Education | $99.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $3,050.09 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Merck Sharp & Dohme LLC | $2,990.70 | 2019-2025 | Zerbaxa, Dificid, Pifeltro |
| Gilead Sciences, INC. | $1,533.21 | 2019-2025 | Biktarvy |
| Insmed, INC. | $897.99 | 2019-2025 | Arikayce, Brinsupri |
| Janssen Biotech, INC. | $740.40 | 2019-2023 | Symtuza |
| Smith+Nephew, INC. | $523.52 | 2019-2025 | Collagenase Santyl, Renasys Touch |
| Shionogi INC | $488.68 | 2021-2025 | Fetroja |
| Theratechnologies INC. | $458.37 | 2019-2025 | Egrifta, Trogarzo |
| Melinta Therapeutics, LLC | $177.78 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $152.68 | 2019-2023 | Nuzyra |
| Stryker Corporation | $124.78 | 2021 | |
| Acelrx Pharmaceuticals, INC. | $120.02 | 2021 | |
| Nabriva Therapeutics, Plc | $119.68 | 2020 | |
| Glaxosmithkline, LLC. | $116.55 | 2021 | |
| Astellas Pharma US INC | $88.60 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $78.44 | 2021-2023 | |
| Allergan, INC. | $76.28 | 2019 | |
| Octapharma USA, INC. | $70.25 | 2020 | |
| Mayne Pharma Commercial LLC | $64.32 | 2020-2022 | |
| Cumberland Pharmaceuticals, INC. | $61.72 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $54.48 | 2023-2025 | Vowst |
| Nestle Healthcare Nutrition INC. | $42.95 | 2023 | |
| Pfizer INC. | $41.99 | 2021 | |
| Abbvie INC. | $40.81 | 2021-2023 | Avycaz |
| Napo Pharmaceuticals INC | $36.12 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $21.41 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $20.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Soosaipillai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.